drugset / Trial / NCT06691035
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
Phase 1
Recruiting
18 enrolled
H. Lee Moffitt Cancer Center and Research Institute
The V Foundation for Cancer Research · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study to determine feasibility and safety of the combination of Dendritic Cell (DC1) vaccines and elacestrant in patients with hormone positive HER2 negative metastatic breast cancer.
Timeline
- Start
- 2024-11-04
- Primary completion
- 2026-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC1 native/mutated ESR1 | Vaccine | 2e+07 cells | Other |
| Subject | DC1 native/mutated ESR1 | Vaccine | 5e+07 cells | Other |
| Subject | Elacestrant | Other / unclassified | 345 mg | Oral |